Floatz logo

Mgta-456

Inherited Metabolic Disorders (IMD)

Magenta Therapeutics, Inc.Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Inherited Metabolic Disorders (IMD) cohort.

Asset / SponsorPhaseRating
Nexiguran Ziclumeran
Intellia Therapeutics
Phase 3B
Hpc, Cord Blood
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Evomela
University of California, San Francisco
Phase 2CCC
Clofarabine
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Busulphan
Memorial Sloan Kettering Cancer Center
Phase 2CCC

View all 17 →

Same molecule, other indications

Mgta-456 is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
acute leukemia of ambiguous lineageDormant
CCC
Indicative ·
53 / 100
View asset →
chronic myeloid leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →